Table 3b.

Regression Findings for Within-Subject Analyses on Correlation Dimension (D2) for Subjects receiving Nux vomica.

	Stage 3				Stage 4
	REM Cycle 1		REM Cycle 2		REM Cycle 1		REM Cycle 2
Electrode Site	Remedy Night	Post-Remedy Change	Remedy Night	Post-Remedy Change	Remedy Night	Post-Remedy Change	Remedy Night	Post-Remedy Change
C3	−.15(.08) †	.26(.11)*	.11(.12)	.12(.28)	−.06(.12)	.06(.16)	−.1(.19)	−.04(.18)
C4	−.07(.12)	.28(.21)	−.08(.09)	.18(.18)	.13(.1)	.08(.15)	.07(.22)	.16(.28)
CZ	−.09(.13)	.2(.18)	−.08(.11)	.01(.25)	−.03(.13)	.36(.17)*	−.01(.11)	.36(.14)*
PZ	.07(.12)	.06(.12)	−.06(.1)	−.05(.24)	.26(.12)*	−.02(.13)	.3(.22)	−.06(.22)
O1	−.03(.11)	.32(.12)*	−.19(.12)	.13(.19)	0(.11)	.14(.2)	.23(.13) †	.04(.12)
O2	0(.12)	.04(.16)	.04(.19)	.11(.16)	.09(.1)	−.01(.17)	.12(.2)	.26(.22)

^†P<0.10,

^*P<0.05,

^**P<0.01,

^***P<0.001.

Reported effects are unstandardized beta coefficients and standard error (in parentheses) for each of the two REM cycles of remedy night (night 22) and the change from night 22 to post-remedy night 23, after controlling for personality, baseline nights, placebo night, and change from placebo to post-placebo night.